Annals of the Rheumatic Diseases Journal

Overview
Identity
Additional Document Info
View All

abbreviation

Ann. Rheum. Dis.

publication venue for

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. 79:1340-1348. 2020-01-01
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial. 77:21-29. 2018-01-01
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. 76:355-363. 2017-01-01
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. 76:346-354. 2017-01-01
Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase IIIb ATTUNE study. 71:857-861. 2012-01-01
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-Year results from the AIM trial. 70:1826-1830. 2011-01-01
Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). 69:1629-1635. 2010-01-01
Correspondence on Tapering towards DMARD-free remission in rheumatoid arthritis 2023-01-01
Correspondence on € Tapering towards DMARD-free remission in rheumatoid arthritis' 2020-01-01
Statins in systemic lupus erythematosus 2018-01-01
Are steroids required for induction therapy and relapses in lupus nephritis? 2013-01-01
Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor α agents [4] 2007-01-01

publisher

BMJ Publishing Group Publisher